
Gameto is a New York clinical-stage biotech developing iPSC-derived ovarian support cell therapies for fertility care.
gametogen.comCrawled Oct 16, 2026
Gameto appointed Dr. Ghassan (Gus) Haddad as chief medical officer.
Gameto appointed Dr. Jaime Knopman as chairwoman of its Clinical Advisory Board. The biotechnology company focuses on advancing treatment options in women’s health and reproductive longevity.
Gameto is seeking an associate to the CEO office to support leadership on strategic, financial, and operational initiatives across investor relations, business development, and scientific teams. The role calls for 1–3 years of investment banking or management consulting experience.
Gameto describes its team as collaborative and united by a mission to use scientific breakthroughs to create products.
Gameto is a biotechnology company in women’s health, co-founded by Dina Radenkovic and Martin Varsavsky.
The company is seeking a medical director of global clinical operations to manage international clinical studies focused on its IVF/IVM product Fertilo. The role is based in Spain and lists a salary range of $90,000–$120,000 plus bonuses.
The company says advances in fertility could improve the female reproductive journey and states that its mission is to transform reproductive health.
Gameto applies biotechnology to fertility treatments and menopause care.
Gameto, Inc. states that its privacy policy covers its websites and explains how the company treats personal and other information it receives or collects.
Gameto, Inc. provides its website and associated websites subject to its Terms and Conditions of Use and other written agreements.
Gameto licenses foundational meiosis intellectual property from Harvard. The license is intended to advance the company's human ovary-in-a-dish platform.
Jan 2026 · GlobeNewswireNews article
Gameto raises a $44 million Series C led by Overwater Ventures, bringing its total funding to $127 million. The financing will support completion of the Phase 3 FIRST trial of Fertilo; the company reports five babies born and more than 20 pregnancies to date.
Aug 2025 · Femtech InsiderNews article
Gameto announces FDA clearance of its IND for Fertilo. The clearance enables the first U.S. Phase 3 trial of an iPSC-based therapy for maturing eggs outside the body.
Jan 2025 · BusinessWireNews article
Gameto announces the first live human birth using Fertilo, its ovarian support cell technology that matures eggs outside the body. The birth is achieved at Santa Isabel Clinic in Lima, Peru.
Dec 2024 · Inside Precision MedicineNews article